Clinical trial Phase 3 Interventional Ages 18 and up

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Run by Novo Nordisk A/S · NCT03811561 · Data updated 2026-11-12

Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2027-11-07.

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.

Research outlook What's coming for Type 2 diabetes: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment1500 (estimated)
SponsorNovo Nordisk A/S
Industry-sponsored
Drugs / interventionsSemaglutide, Placebo (semaglutide)
Locations230 sites (Brazil, Bulgaria, Canada, Czechia, Germany, Greece, India, Israel and more)
Trial IDNCT03811561 on ClinicalTrials.gov

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or female, age greater than or equal to 18 years at the time of signing informed consent
* Diagnosed with type 2 diabetes mellitus.
* HbA1c of 7.0-10.0% (53-86 mmol/mol) (both inclusive).
* Eye inclusion criteria (both eyes must meet all criteria):
* Early Treatment Diabetic Retinopathy Study (ETDRS) level of 10-75 (both inclusive) evaluated by fundus photography and confirmed by central reading centre
* No ocular or intraocular treatment for diabetic retinopathy or diabetic macular oedema six months prior to the day of screening.
* No anticipated need for ocular or intraocular treatment for diabetic retinopathy or diabetic macular oedema within three months after randomisation.
* Best-corrected visual acuity greater than or equal to 30 letters using the ETDRS visual acuity protocol
* No previous treatment with pan-retinal laser photocoagulation
* No substantial non-diabetic ocular condition that, in the opinion of the ophthalmologist, would impact diabetic retinopathy or diabetic macular oedema progression during the trial
* No substantial media opacities that would preclude successful imaging

Exclusion Criteria:

* Any of the following: myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening
* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
* Subjects presently classified as being in New York Heart Association (NYHA) Class IV
* Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of eGFR less than 30 ml/min/1.73 m\^2
* Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
* Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed
* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using highly effective contraceptive methods
* Concurrent treatment with any GLP-1 receptor agonist or DPP-4 inhibitor from randomisation.
* Receipt of any investigational medicinal product within 30 days before screening
* Previous participation in this trial. Participation is defined as randomisation
* Known or suspected hypersensitivity to trial products or related products
* Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol

Where it's running

  • Synexus Rsch /Cnt Phnx Med C
    Phoenix, Arizona, United States
  • Del Sol Research Management, LLC
    Tucson, Arizona, United States
  • South Arizona VA Healthcare System
    Tucson, Arizona, United States
  • Synexus Cln Rsrch Inc - Orange Gro FP
    Tucson, Arizona, United States
  • Southern California Res Ctr
    Coronado, California, United States
  • Fdrc
    Costa Mesa, California, United States
Show 44 more locations
  • Advanced Investigative Medicine, Inc.
    Hawthorne, California, United States
  • Diabetes/Lipid Mgmt & Res Ctr
    Huntington Beach, California, United States
  • Scripps Whittier Diabetes Inst
    La Jolla, California, United States
  • Torrance Clin Res Inst, Inc.
    Lomita, California, United States
  • Angel City Research, Inc.
    Los Angeles, California, United States
  • Downtown LA Res Ctr. Inc.
    Los Angeles, California, United States
  • Riverside University Health System Medical Center
    Moreno Valley, California, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California, United States
  • Clinical Trials Research_Sacramento_0
    Sacramento, California, United States
  • UCLA Diabetes Center at Santa Monica
    Santa Monica, California, United States
  • Coastal Metabolic Research Center
    Ventura, California, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California, United States
  • Barbara Davis Center
    Aurora, Colorado, United States
  • Rocky Mount Reg VA Med-DN
    Aurora, Colorado, United States
  • Chase Medical Research LLC
    Waterbury, Connecticut, United States
  • Innovative Research of W FL
    Clearwater, Florida, United States
  • Est Cst Inst for Rsrch,Jksnvil
    Jacksonville, Florida, United States
  • Reyes Clinical Research, Inc
    Miami, Florida, United States
  • Renstar Medical Research
    Ocala, Florida, United States
  • Atlanta Diabetes Associates
    Atlanta, Georgia, United States
  • Endo Res Solutions Inc
    Roswell, Georgia, United States
  • Apex Medical Research Inc
    Chicago, Illinois, United States
  • The University Of Chicago
    Chicago, Illinois, United States
  • American Health Network of Indiana, LLC_Avon
    Avon, Indiana, United States
  • American Health Network of Indiana, LLC_Greenfield
    Greenfield, Indiana, United States
  • Iowa Diab & Endo Res Center
    West Des Moines, Iowa, United States
  • VA Medical Center
    Lexington, Kentucky, United States
  • Kentucky Diabetes-Endocrinology Center
    Lexington, Kentucky, United States
  • The Research Group of Lexington LLC
    Lexington, Kentucky, United States
  • L-MARC Research Center
    Louisville, Kentucky, United States
  • Four Rivers Clinical Research Inc
    Paducah, Kentucky, United States
  • MedStar Hlth Res Institute
    Hyattsville, Maryland, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts, United States
  • Boston Medical Center_Cary
    Boston, Massachusetts, United States
  • Joslin Center For Diabetes
    Boston, Massachusetts, United States
  • Joslin Diabetes Center
    Boston, Massachusetts, United States
  • Michigan Medicine
    Ann Arbor, Michigan, United States
  • Synexus Clinical Research US, Inc._Tempe_0
    Richfield, Minnesota, United States
  • Diabetes & Endo Specialists Inc
    Chesterfield, Missouri, United States
  • Palm Research Center Inc-Vegas
    Las Vegas, Nevada, United States
  • Southern New Hampshire Diabete
    Nashua, New Hampshire, United States
  • Lovelace Scientific Resources Inc
    Albuquerque, New Mexico, United States
  • University of New Mexico
    Albuquerque, New Mexico, United States
  • NYC Research, Inc.
    New York, New York, United States

+180 more sites. See ClinicalTrials.gov for the full list.

Study contacts

  • Principal investigator: Clinical Reporting Anchor and Disclosure (1452) — Novo Nordisk A/S

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.